Trials / Conditions / Metastatic Rectal Adenocarcinoma

Metastatic Rectal Adenocarcinoma

18 registered clinical trials studyying Metastatic Rectal Adenocarcinoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	xDRIVE in Metastatic Colorectal Cancer NCT06929338	First Ascent Biomedical Inc.	—
Withdrawn	Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Met NCT06575725	City of Hope Medical Center	Phase 2
Withdrawn	Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cance NCT05356897	Academic and Community Cancer Research United	Phase 2
Active Not Recruiting	FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Micro NCT05627635	City of Hope Medical Center	Phase 1 / Phase 2
Active Not Recruiting	Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorecta NCT05308446	National Cancer Institute (NCI)	Phase 2
Completed	A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer NCT05130060	Mayo Clinic	Phase 1
Unknown	BRIANSTORM - Early Identification of Patients With Brain Metastases NCT05185557	Aarhus University Hospital	—
Active Not Recruiting	LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastat NCT04616183	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the S NCT04599140	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Can NCT04044430	University of California, San Francisco	Phase 1
Completed	Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metast NCT04362839	City of Hope Medical Center	Phase 1
Active Not Recruiting	Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type C NCT03992456	Academic and Community Cancer Research United	Phase 2
Terminated	Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Tr NCT03765736	Academic and Community Cancer Research United	—
Completed	TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Ca NCT04109924	Roswell Park Cancer Institute	Phase 2
Terminated	Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer NCT03592641	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unres NCT04017650	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally NCT03300544	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer NCT02874885	M.D. Anderson Cancer Center	—